Abstracts tagged "lupus nephritis and macrophages"

Abstract Number: 2099 • 2018 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Elliott Klein², Jay S. Fine², Gerald Nabozny³, Meera Ramanujam² and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE) that adds substantial morbidity and mortality. Passive transfer of pre-formed nephritogenic antibodies…
Abstract Number: 968 • 2016 ACR/ARHP Annual Meeting
Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Ranjan Gupta¹, Akhilesh Yadav² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Alternatively activated (M2) macrophages are the major macrophage subtype infiltrating the glomeruli in lupus nephritis (LN). CD163 is a marker of M2 macrophages. In…
Abstract Number: 2180 • 2014 ACR/ARHP Annual Meeting
Macrophage Depletion Ameliorates Nephritis Induced By Pathogenic Antibodies
Samantha Chalmers¹, Leal Herlitz², Violeta Chitu³, Richard Stanley⁴ and Chaim Putterman⁵, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Columbia-Presbyterian Medical Center, New York, NY, ³Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, ⁴Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NJ, ⁵Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose Kidney involvement affects up to 60% of lupus patients, and is responsible for significant morbidity and mortality. Previous studies using a variety of methods…
Abstract Number: 172 • 2013 ACR/ARHP Annual Meeting
Transcript Profiling Of Kidney Biopsies From Chinese Patients With Lupus Nephritis Suggests a Prevalence Of Infiltrating CD8+ T Cells, Monocytes/Macrophages, and B Cells In ISN/RPS Class IV Disease
Zheng Liu¹, Chris Morehouse¹, Xinfang Huang², Philip Brohawn¹, Nan Shen³, Gabor G. Illei⁴, Yihong Yao¹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ³Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, cincinnati, OH, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD
Transcript profiling of kidney biopsies from Chinese patients with lupus nephritis suggests a prevalence of infiltrating CD8+ T cells, monocytes/macrophages, and B cells in ISN/RPS…
Abstract Number: 688 • 2012 ACR/ARHP Annual Meeting
Expression of the Mer Receptor Tyrosine Kinase On Peripheral Blood Mononuclear Cells From Systemic Lupus Erythematosus Patients
Brendan A. Hilliard¹, Gaetano Zizzo¹, Margaret K. Linan¹ and Philip L. Cohen², ¹Medicine, Temple University School of Medicine, Philadelphia, PA, ²Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: The Mer tyrosine kinase (Mertk) is necessary for optimal removal of apoptotic cells in animal models. Its ligation by apoptotic cell-bound protein S…
Abstract Number: 2677 • 2012 ACR/ARHP Annual Meeting
IL-23 Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 Mice
Hao Li¹, Hui-Chen Hsu², Qi Wu³, PingAr Yang³, Jun Li⁴, Daniel Cua⁵, Mohamed Oukka⁶ and John D. Mountz⁷, ¹Microbiology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁶Pediatrics, Seattle, WA, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Failure to clear apoptotic bodies is a central pathogenic mechanism for SLE. We have observed that spontaneous systemic autoimmunity and lupus in BXD2 mice…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].